Opinion|Videos|March 12, 2025
Insights From JUPITER-02: Plasma EBV Levels and Toripalimab in R/M NPC
Author(s)Nagashree Seetharamu, MD, MBBS
A panelist discusses how low baseline EBV levels still showed benefit from toripalimab in JUPITER-02, though EBV status influences treatment decisions and alternative markers are needed for EBV-negative cases.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Please review subgroup analyses from JUPITER-02 for EBV copy number at baseline.
- The patient had detectable but low plasma EBV levels (under 2000 IU/ml).
- What are your thoughts on overall survival between treatment arms for patients with a baseline plasma EBV copy number of less than 2000 IU/ml?
- Please continue to discuss the role of EBV titers and treatment decisions.
- How do plasma EBV levels influence your treatment approach?
- Do your expectations regarding response to therapy change based on plasma EBV levels?
- What if a patient has EBV-negative disease?
- Are there other disease response indicators that might be useful in this patient population?
Advertisement
Related to this article
TRE-515 could improve the durability of response in combination with KRAS inhibition in patients with advanced non–small cell lung cancer, investigators stated.
FDA expands pirtobrutinib into first-line CLL/SLL for adults without 17p deletion, delivering major PFS gains versus bendamustine-rituximab.
Submission of a new drug application for zipalertinib plus chemotherapy has begun under the FDA's RTOR program, based on phase 3 REZILIENT3 data showing a 6-month PFS gain.
Insurance hurdles and steep out-of-pocket costs often delay or prevent patients from filling specialty oral blood cancer drugs, even after eventual approvals.
Telehealth transplant consults help patients with multiple myeloma overcome racial, age, and rural barriers, speeding eligibility screening and expanding access to specialists.
The MUC16xCD3 bispecific antibody showed a 73% response rate in phase 1/2 trial; the sponsor announced plans for a potential registrational cohort and phase 3 trial.
Five myeloma experts share their top takeaways from IMS 2026, including the CERVINO trial and long-term follow-up from the PERSEUS study.
Giredestrant plus everolimus reduced the risk of progression or death by 44% in the ITT population and 62% in ESR1-mutated disease in phase 3 evERA data published in NEJM.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Ubamatamab Shows Durable Responses in Low-Grade Serous Ovarian Cancer
2
Pirtobrutinib Gains FDA Approval for Frontline CLL/SLL in Select Patients
3
What Stood Out at IMS 2026? Five Myeloma Experts Weigh In
4
Telehealth May Offer a Path to More Equitable Myeloma Transplant Access
5